Nelarabine injection
Products billed under this code include Arranon, Nelarabine.
Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Arranon, Nelarabine.
Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Arranon | Sandoz Inc. | 00078-0683-61 | 5 | $204.36 |
| Arranon | Sandoz Inc. | 66758-0165-94 | 5 | $204.36 |
| Nelarabine | Sagent Pharmaceuticals | 25021-0259-50 | 5 | $204.36 |
| Nelarabine | Sagent Pharmaceuticals | 25021-0259-51 | 30 | $1,226.16 |
| Nelarabine | XGen Pharmaceuticals DJB, Inc. | 39822-0650-01 | 5 | $204.36 |
| Nelarabine | XGen Pharmaceuticals DJB, Inc. | 39822-0650-06 | 30 | $1,226.16 |
| Nelarabine | Dr. Reddy's Laboratories Inc. | 43598-0142-06 | 30 | $1,226.16 |
| Nelarabine | Dr. Reddy's Laboratories Inc. | 43598-0142-11 | 5 | $204.36 |
| Nelarabine | Alembic Pharmaceuticals Inc. | 62332-0813-50 | 5 | $204.36 |
| Nelarabine | Amneal Pharmaceuticals, LLC | 70121-1743-04 | 30 | $1,226.16 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 70710-1726-01 | 5 | $204.36 |
| Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 70710-1726-08 | 30 | $1,226.16 |
| Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 70710-1839-01 | 5 | $204.36 |
| Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 70710-1839-08 | 30 | $1,226.16 |
| Nelarabine | Meitheal Pharmaceuticals Inc. | 71288-0165-53 | 30 | $1,226.16 |
| Nelarabine | Meitheal Pharmaceuticals Inc. | 71288-0165-54 | 5 | $204.36 |
| Nelarabine | Novadoz Pharmaceuticals LLC | 72205-0154-01 | 5 | $204.36 |
| Nelarabine | Novadoz Pharmaceuticals LLC | 72205-0154-04 | 30 | $1,226.16 |
| Nelarabine | Shorla Oncology Inc. | 81927-0111-01 | 5 | $204.36 |
| Nelarabine | Shorla Oncology Inc. | 81927-0111-06 | 30 | $1,226.16 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $40.872 | −$24.535 | 50 MG | Nelarabine injection | v1, posted September 17, 2026 |
| 3Q26 | $65.407 | +$12.70 | 50 MG | Nelarabine injection | v1, posted September 15, 2026 |
| 2Q26 | $52.707 | −$12.453 | 50 MG | Nelarabine injection | v1, posted September 15, 2026 |
| 1Q26 | $65.16 | −$14.702 | 50 MG | Nelarabine injection | v1, posted September 15, 2026 |
| 4Q25 | $79.862 | +$16.483 | 50 MG | Nelarabine injection | v1, posted September 8, 2026 |
| 3Q25 | $63.379 | +$0.195 | 50 MG | Nelarabine injection | v1, posted March 10, 2026 |
| 2Q25 | $63.184 | −$11.571 | 50 MG | Nelarabine injection | v1, posted March 10, 2026 |
| 1Q25 | $74.755 | +$2.228 | 50 MG | Nelarabine injection | v1, posted December 19, 2025 |
| 4Q24 | $72.527 | −$0.793 | 50 MG | Nelarabine injection | v1, posted June 11, 2025 |
| 3Q24 | $73.32 | −$28.605 | 50 MG | Nelarabine injection | v1, posted June 11, 2025 |
| 2Q24 | $101.925 | −$9.057 | 50 MG | Nelarabine injection | v1, posted March 11, 2025 |
| 1Q24 | $110.982 | −$5.665 | 50 MG | Nelarabine injection | v1, posted December 19, 2024 |
| 4Q23 | $116.647 | −$12.347 | 50 MG | Nelarabine injection | v1, posted October 10, 2024 |
| 3Q23 | $128.994 | −$0.841 | 50 MG | Nelarabine injection | v1, posted June 5, 2024 |
| 2Q23 | $129.835 | −$5.448 | 50 MG | Nelarabine injection | v1, posted February 23, 2024 |
| 1Q23 | $135.283 | +$7.892 | 50 MG | Nelarabine injection | v1, posted December 6, 2023 |
| 4Q22 | $127.391 | −$2.749 | 50 MG | Nelarabine injection | v1, posted June 22, 2023 |
| 3Q22 | $130.14 | −$6.795 | 50 MG | Nelarabine injection | v1, posted June 9, 2023 |
| 2Q22 | $136.935 | −$18.962 | 50 MG | Nelarabine injection | v1, posted December 14, 2022 |
| 1Q22 | $155.897 | $0.00 | 50 MG | Nelarabine injection | v1, posted June 8, 2022 |
| 4Q21 | $155.897 | +$3.456 | 50 MG | Nelarabine injection | v1, posted June 2, 2022 |
| 3Q21 | $152.441 | +$0.544 | 50 MG | Nelarabine injection | v1, posted June 2, 2022 |
| 2Q21 | $151.897 | +$0.009 | 50 MG | Nelarabine injection | v1, posted March 1, 2022 |
| 1Q21 | $151.888 | – | 50 MG | Nelarabine injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.